Macular Degeneration: Regular Eye Injections Key to Vision Preservation
Macular degeneration, a progressive eye condition, can be managed with regular eye injections containing anti-VEGF medication. This treatment, offered by major pharmaceutical companies like Genentech, Roche, and F. Hoffmann-La Roche Ltd., helps prevent vision loss by stopping abnormal blood vessel growth under the retina.
These injections, given every 4 to 6 weeks, are crucial for maintaining vision. Discontinuing them can lead to further macular damage and vision decline, either rapidly or slowly. Doctors may suggest pausing treatments if the condition seems inactive, but patients should adhere to their treatment plans to avoid potential vision loss.
Macular degeneration requires ongoing management with anti-VEGF eye injections. Regular treatment helps preserve vision, but discontinuing injections can lead to vision decline. Patients should consult their doctors about their specific treatment plans.
Read also:
- Abu Dhabi initiative for comprehensive genetic screening, aiming to diagnose over 800 conditions and enhance the health of future generations in the UAE.
- Elderly shingles: Recognizing symptoms, potential problems, and available treatments
- Exploring the Reasons, Purposes, and Enigmas of Hiccups: Delving into Their Origins, Roles, and Unsolved Aspects
- Various forms of cataracts include nuclear, pediatric, traumatic, and additional types
